FINANCINGS

Abeona Therapeutics Corp. closed a $3.6 million financing.

Alimera Sciences Inc. inked an agreement with Deerfield Management and certain affiliates, which agreed to purchase approximately $50 million in Alimera preferred shares.

Allena Pharmaceuticals Inc. raised $25 million in a series B financing.

Anergis SA said it closed a series B financing round totaling $15 million.

Apellis Pharmaceuticals Inc. completed a $33 million private placement of its series C preferred stock.

Ascendis Pharma A/S completed a $60 million series D financing.

Audentes Therapeutics Inc. closed a $42.5 million series B financing.

Canbridge Life Sciences Inc. closed a $10 million series A round.

Histogenics Corp. priced its IPO for expected net proceeds of approximately $57.2 million.

Medgenics Inc. completed a public offering for gross proceeds of about $24.2 million.

Nanobiotix SA completed a private placement for a total subscription amount of $13 million.

Naurex Inc. raised $80 million in a series C round.

Neothetics Inc. closed its IPO of 4.65 million shares at $14 each, raising approximately $60.5 million.

PMV Pharmaceuticals Inc. completed a $30 million series A financing.

Seres Health Inc. closed a $48 million series C financing.

DEALS

Astrazeneca plc signed an agreement to give Cancer Research UK access to its library of 2 million compounds and to a new screening facility currently under construction in Cambridge, UK.

Dynavax Technologies Corp. regained full rights to DV1179, its bifunctional inhibitor of Toll-like receptors 7 and 9, from Glaxosmithkline plc.

Evotec AG entered exclusive negotiations with Sanofi SA on a major multicomponent strategic alliance over the next five years.

Geneuro SA signed a deal with Les Laboratoires Servier involving multiple sclerosis antibody GNbAC1.

Modern Biosciences plc signed a deal with Janssen Biotech Inc. that covers a series of preclinical bone-protective compounds in development for rheumatoid arthritis.

Nordic Nanovector ASA and Affibody AB entered an agreement to develop radioimmunotherapies for multiple myeloma.

Novartis AG returned full rights to the MEK inhibitor binimetinib to Array Biopharma Inc.

Otsuka Pharmaceutical Co. Ltd. offered $17 per share in cash, or $3.5 billion, to acquire Avanir Pharmaceuticals Inc.

Vaccinex Inc. entered a collaboration with Janssen Research & Development LLC to develop cancer drugs.

. . . AND MORE

Bristol-Myers Squibb Co. received an FDA complete response letter for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of HCV.

Clementia Pharmaceuticals Inc. said the EMA granted orphan medicinal product designation for palovarotene for the treatment of fibrodysplasia ossificans progressiva.

Half of the more than 100 firms targeted by hackers out to intercept confidential data regarding potentially market-moving disclosures are biotech companies, according to a report by FireEye.

Karyopharm Therapeutics Inc. said Selinexor received orphan drug designation from the EMA to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

The EU and Africa are doubling research efforts to develop new and better medicines for poverty-related diseases affecting sub-Saharan Africa.